Carl Zeiss Medit Stock Price, News & Analysis

ZEISS Medical Technology (OTC:CZMWY) will showcase its advanced retina portfolio at EURETINA 2025 in Paris, highlighting several key innovations. The company announced the CE mark approval of CIRRUS® PathFinder™, an AI-powered OCT data review tool, and introduced the TDC VELOCE™, a new high-speed cutter for the EVA NEXUS™ platform.

Key developments include CLARUS® 700 with ICGA capabilities, the AI-ready ZEISS Research Data Platform (RDP), and updates to ZEISS CALLISTO eye® software offering up to 30% higher magnification. The company's comprehensive ecosystem spans diagnostic imaging, digital workflow tools, and vitreoretinal surgical technologies, positioning ZEISS as one of few companies offering complete retinal care solutions.

For context, ZEISS Medical Technology reported revenue of €2,066.1m in fiscal year 2023/24 and employs 5,730 people globally, with over 50% based in the USA, Japan, Spain, and France.

ZEISS (OTC:CZMWY) has received CE mark approval for its CIRRUS PathFinder, an AI-powered clinical support tool for OCT interpretation. The technology integrates proprietary deep learning algorithms to automatically identify abnormal macular OCT B-scans, enhancing diagnostic workflows and patient care efficiency.

The new software release includes AI-enhanced OCTA image quality, multi-layer segmentation, and expanded reference database that is triple the size of the previous version. The system can assess hundreds of scans simultaneously in real-time, flagging areas requiring detailed imaging without third-party platforms.

The tool is available in select markets as a licensed element within the new CIRRUS software update, which also features enhanced cybersecurity measures and seamless integration with legacy OCT data.

ZEISS Medical Technology has received NMPA approval in China for its CLARUS 700 fundus imaging device, marking a significant advancement in retinal diagnostics. The device offers ultra-widefield, high-resolution imaging with True Color capabilities and Fluorescein Angiography functionality. The CLARUS 700 captures 133° in a single image and up to 267° with multiple captures, providing comprehensive visualization from the macula to the peripheral retina. Key features include PrecisionFocus for detailed region viewing, QuickCompare for pathology monitoring, and AutoBright for efficient image analysis. The device aims to enhance diagnostic precision and patient comfort in the Chinese market while supporting improved patient vision preservation through advanced retinal workflow integration.

ZEISS has unveiled its new AI-powered Research Data Platform (RDP) at ARVO 2025, marking a significant advancement in ophthalmic research. The cloud-based platform enables seamless integration of clinical and research data, allowing researchers to accelerate discoveries through AI-driven analysis.

The company has also highlighted its ongoing collaboration with Boehringer Ingelheim to develop personalized eye care solutions. This partnership focuses on earlier detection and prediction capabilities for chronic retinal diseases using AI technology.

Key features of the ZEISS RDP include:

• AI-powered tools for converting research hypotheses into quantifiable biomarkers
• Unified data management across multiple sources
• Streamlined research workflow integration with clinical systems

The platform will launch in select countries throughout 2025 following successful pilot testing. Expert talks featuring leading ophthalmologists will be presented at ARVO 2025 to discuss AI's role in future eye care practices.

ZEISS Medical Technology has achieved a significant milestone with over 2 million cataract cases planned using the ZEISS VERACITY Surgery Planner in the U.S. This digital planning solution has demonstrated up to 60% time savings per eye compared to traditional paper planning.

The company will showcase its innovations at ASCRS 2025 in Los Angeles, including the newly available ZEISS MEL 90 and VISUMAX 800 systems for refractive treatments. The VISUMAX 800 with SMILE pro software enables faster treatment, creating lenticules in under 10 seconds with a 2 MHz laser pulse rate.

For the first time, ZEISS will present cataract surgical solutions from its companies DORC and FCI, featuring the DORC EVA NEXUS surgical system and VisionBlue anterior stain, which has been used in over 10 million cataract surgeries. The showcase will also include the FDA-approved Eyejet 20C from Morcher, designed to prevent toric IOL rotation.

ZEISS Medical Technology has received FDA 510(k) clearance for its INTRABEAM 700, an advanced platform for intraoperative radiation therapy (IORT). The system features robotic-assisted precision through the INTRABEAM SMART Stand, offering enhanced maneuverability and positioning control for neurooncology and breast cancer therapy.

The platform introduces SMART workflow efficiency with digital-first architecture, including sterile SMART Spherical Applicators, digital-assisted applicator management, and the redesigned Radiance™ treatment planning simulation software. The system enables seamless integration into hospital information systems and provides integrated applicator recognition through RFID technology.

ZEISS INTRABEAM is currently involved in multiple clinical studies, including phase 2 and 3 trials for brain metastases, glioblastoma, and breast cancer, with publications expected between 2025-2027.

ZEISS Medical Technology announced that ILM-Blue® from DORC has received NMPA approval in China, expanding its global reach. The product, used for staining and distinguishing the inner limiting membrane during vitreoretinal surgery, has been utilized in over 900,000 procedures worldwide since 2010.

ILM-Blue® is the first DORC posterior dye product available in China and remains the only ILM staining solution approved by the FDA. In the U.S., where it's marketed as TissueBlue®, it's ranked as the #1 preferred ILM stain among retina surgeons. The product helps facilitate membrane removal and reduces the risk of retinal damage during surgery.

ZEISS Medical Technology has received approval from China's National Medical Products Administration (NMPA) for its VISUMAX 800 with SMILE pro software, designed for treating nearsightedness with or without astigmatism. This latest femtosecond laser system enters the Chinese market after successful treatment of over 10 million eyes worldwide.

The system offers significant improvements including:

• Faster treatment with lenticule creation in under 10 seconds using 2 MHz laser pulse rate
• Enhanced workflow features including CentraLign centration aid and OcuLign cyclotorsion adjustment
• VISULYZE user nomograms for data collection and analysis
• Smaller footprint and compatibility with various patient beds

ZEISS Medical Technology announced FDA approval for its MEL 90 excimer laser, receiving simultaneous approval for treating myopia, hyperopia, and mixed astigmatism. The technology integrates with the VISUMAX 800 with SMILE pro, enhancing ZEISS' laser vision correction market leadership.

The MEL 90 features Triple-A (Advanced Ablation Algorithm) technology, offering high accuracy and tissue-saving ablation. It can ablate 1 diopter in 1.3 seconds during LASIK procedures at 500 Hz. The system includes an active eye tracker, intuitive interface, and flexible touch screen positioning for improved workflow efficiency.

This approval completes ZEISS' Corneal Refractive Workflow, providing U.S. surgeons with an integrated system for enhanced patient outcomes and practice efficiency. The technology is immediately available in the U.S. market.